

FDA Lambastes Payment Model and its Impact on U.S. 'Anemic' Biosimilar Market

July 20, 2018

ATTORNEYS

Ropka, PhD, Stacie

PRACTICE AREAS

FDA

Intellectual Property

Mari Serebrov

BioWorld

Axinn partner Stacie Ropka, PhD was quoted in the *BioWorld* article, "FDA Lambastes Payment Model and its Impact on U.S. 'Anemic' Biosimilar Market."

Click [here](#) to access the article.